Clinical trial
Open Label Phase 2 Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia. A FILO Study
NCT06547866 is registered in ClinicalTrials.gov with French Innovative Leukemia Organisation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open Label Phase 2 Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia. A FILO Study
- Lead sponsor
- French Innovative Leukemia Organisation
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 1, 2025
- Completion date
- December 31, 2031
- Enrollment
- 102 (estimated)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.